Compositions and methods for delivery of poorly soluble drugs
View Patent ↗Described herein are compositions comprising particles of poorly soluble drugs encapsulated by stabilizers. Further described are pharmaceutical compositions comprising such encapsulated compositions. Also described are methods of making such encapsulated particle compositions, and methods of making the corresponding pharmaceutical compositions. The encapsulated particle compositions described herein allow poorly soluble drugs to be administered with good bioavailability by routes that are non-invasive to patients, such as by oral administration.
1. A particle delivery system (PDS) comprising dry particles having an average diameter of less than about 2 mm, wherein the dry particles comprise a poorly soluble drug and a stabilizer comprising polyethylene glycol (PEG), wherein
the amount of the poorly soluble drug present in the dry particles ranges from about 0.2% to about 4% by mass of the dry particles,
the poorly soluble drug is encapsulated by the stabilizer,
the poorly soluble drug comprises at least one drug selected from codeine, fentanyl, hydrocodone, hydromorphone, morphine, methylnaltrexone, nalbuphine, nalmefene, oxymorphone, oxycodone, pethidine, tramadol, and combinations or mixtures thereof,
and wherein the stabilizer is water soluble.
2. The composition of claim 1 , wherein the PEG has an average molecular weight ranging from about 100 Daltons to about 100,000 Daltons.
3. The PDS of claim 2 , wherein the PEG is PEG 3350.
4. The PDS of claim 1 , further comprising a surfactant.
5. The PDS of claim 4 , wherein the surfactant is a nonionic surfactant.
6. A pharmaceutical composition comprising the PDS of claim 1 and at least one second compound.
7. The pharmaceutical composition of claim 6 , wherein the composition is formulated for oral administration.
8. The pharmaceutical composition of claim 6 , wherein the at least one second compound is a drug chosen from opioid receptor antagonists, anti-inflammatory drugs, analgesics, and combinations or mixtures thereof.
9. The pharmaceutical composition of claim 8 , wherein the drug comprises an opioid receptor antagonist.
10. The pharmaceutical composition of claim 9 , wherein the drug comprises naloxone or a pharmaceutically acceptable salt thereof.
11. The pharmaceutical composition of claim 10 , wherein the naloxone salt is naloxone HCl.